Skip to main content

Month: August 2025

BIO-key, Provider of Identity and Access Management Solutions with Enhanced Biometrics, Hosts Q2 Investor Call Wed. Aug. 13th at 10am ET

HOLMDEL, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) — BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer Identity and Access Management solutions featuring passwordless, phoneless, and tokenless Identity-Bound Biometric authentication, will host its second quarter 2025 investor call on Wednesday, August 13th at 10 a.m. ET. Results will be released before the stock market opens that morning. Mike DePasquale, Chairman & CEO and Cecilia Welch, CFO will lead the conference call and host a Q&A session.Call Details  Date / Time:Call Dial In #:Live Webcast / Replay:Audio Replay: Wednesday, August 13th at 10 a.m. ET1-877-418-5460 U.S. or 1-412-717-9594 Int’lWebcast & Replay Link – Available for 3 months.1-877-344-7529 U.S. or 1-412-317-0088 Int’l; code 8281392About BIO-key International,...

Continue reading

Rackspace Technology Launches Cloud Management Platform with New Capabilities for Hybrid Environments

Next-gen upgrades empower organizations to streamline workload operations and optimize their entire cloud infrastructure from a single AI-enabled platform SAN ANTONIO, Aug. 05, 2025 (GLOBE NEWSWIRE) — Rackspace Technology® (NASDAQ: RXT), a leading end-to-end hybrid cloud and AI solutions company, today announced the launch of the Rackspace Cloud Management Platform, which includes next-gen upgrades to the Rackspace Managed Cloud (“RMC”) offering. The platform provides customers with a single robust framework that leverages best-in-class AI-enabled tools, empowering organizations to streamline workload operations, accelerate digital transformation, and more efficiently manage modern hybrid and multicloud environments. In addition to providing customers with full-stack observability, intelligent application optimization, and adherence...

Continue reading

StoneX Completes Acquisition of The Benchmark Company to Expand Investment Banking Capabilities

NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) — StoneX Group Inc. (NASDAQ: SNEX), a global financial services firm connecting clients to the markets across asset classes and geographies, today announced the successful completion of its acquisition of The Benchmark Company, LLC (“Benchmark”), a leading provider of investment banking, equity research, and institutional sales and trading services. The transaction, originally announced on March 11, 2025, adds a complementary suite of capabilities to StoneX’s existing offerings, enhancing its capital markets offering and establishing a deeper presence in Investment Banking and Equity Research. Strategic Fit and Integration Plans Benchmark brings a seasoned investment banking team, as well as professionals across institutional sales, trading, and equity research. The firm is recognized for...

Continue reading

Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

NXP900 becomes the lead drug candidate after successfully completing the Phase 1a dose escalation study in patients with advanced solid tumors and a drug-drug interaction study in healthy volunteers; initiation of Phase 1b program is imminent Strengthened cash position following a July At-The-Market (ATM) shares acquisition by a healthcare-dedicated institutional investor; June 30, 2025 proforma cash position of approximately $39 millionFORT LEE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the second quarter 2025 and provided...

Continue reading

Hillman Reports Second Quarter 2025 Results

Raises mid-point of 2025 Net Sales and Adj. EBITDA guidance Board approves $100 million Share Repurchase Program CINCINNATI, Aug. 05, 2025 (GLOBE NEWSWIRE) — Hillman Solutions Corp. (Nasdaq: HLMN) (the “Company” or “Hillman”), a leading provider of hardware products and merchandising solutions, reported financial results for the thirteen and twenty-six weeks ended June 28, 2025. Second Quarter 2025 Highlights (Thirteen weeks ended June 28, 2025)Net sales increased 6.2% to $402.8 million compared to $379.4 million in the prior year quarter Net income totaled $15.8 million, or $0.08 per diluted share, compared to $12.5 million, or $0.06 per diluted share, in the prior year quarter Adjusted diluted EPS1 totaled $0.17 per diluted share compared to $0.16 per diluted share in the prior year quarter Adjusted EBITDA1 increased to $75.2...

Continue reading

Surgery Partners, Inc. Announces Second Quarter 2025 Results

Reaffirms Full Year 2025 Guidance BRENTWOOD, Tenn., Aug. 05, 2025 (GLOBE NEWSWIRE) — Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights (All comparisons are year-over-year unless otherwise noted)Revenue increased 8.4% for the second quarterSame-facility revenues increased 5.1% for the second quarter Same-facility cases increased 3.4% for the second quarterNet loss attributable to Surgery Partners, Inc. was $2.5 million for the second quarterAdjusted EBITDA increased 9.0% to $129.0 million for the second quarter2025 GuidanceFull year 2025 revenue and Adjusted EBITDA guidance reaffirmed to be in the range of $3.30 billion to...

Continue reading

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

– Full data for Phase 1/2 dose expansion cohort expected by year-end 2025 – – Cash runway into the second quarter of 2026 – BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quarter 2025, and provided a corporate update. “The second quarter was a key inflection point for Sensei, as we now transition from early response-focused readouts to longer-term and commercially relevant efficacy signals with the maturity of the data from our Phase 1/2 study of solnerstotug,” said John Celebi, President and CEO of Sensei. “Solnerstotug has demonstrated a favorable safety profile and in combination with...

Continue reading

Smithfield’s “We Speak Pork” Campaign Features Pork So Good It Speaks for Itself

Creative platform designed to drive awareness among Gen Z and Millennials, expand Smithfield’s leadership in packaged meats segmentI sizzle, smoke, and crisp to perfection. So let me do the talking.Smithfield – We Speak PorkI basically invented the ham sandwich.Smithfield – We Speak PorkI can get crispy.Smithfield – We Speak PorkNow we’re talking.Smithfield – We Speak PorkI put on my best marinade for you.SMITHFIELD, Va., Aug. 05, 2025 (GLOBE NEWSWIRE) — Smithfield® has launched a new national advertising campaign, “We Speak Pork,” showcasing pork so good it speaks for itself. The video campaign features Emmy Award-winning writer, actor and comedian Ben Schwartz as the voice of Smithfield’s portfolio of products, including bacon, Prime Fresh...

Continue reading

Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)

TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces through its subsidiary, Huge Biopharma Australia Pty Ltd., that it has received the clinical study report (CSR) for the trial entitled “A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-MS in Healthy Adult Participants.” The CSR concludes that there were no safety or tolerability concerns that were identified in healthy participants following treatment with consecutive daily dosing of Lucid-MS. Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound with a unique...

Continue reading

Hillman’s Board of Directors Approves $100 Million Share Repurchase Program

Share Repurchase Program is Hillman’s first since becoming public in 2021 CINCINNATI, Aug. 05, 2025 (GLOBE NEWSWIRE) — Hillman Solutions Corp. (Nasdaq: HLMN) (the “Company” or “Hillman”), a leading provider of hardware products and merchandising solutions, announced that its Board of Directors has authorized an initial share repurchase program (“SRP”) for up to $100 million of the Company’s outstanding common stock. This new authorization permits shares of common stock to be repurchased from time to time at management’s discretion, through a variety of methods, including a 10b5-1 trading plan, open market purchases, privately negotiated transactions or transactions otherwise in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended. This is the first SRP that Hillman has implemented since becoming...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.